drugset / Trial / NCT02226653

A Study of Evacetrapib in Healthy Japanese Participants

NCT02226653

Phase 1 Completed 48 enrolled Eli Lilly and Company
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to determine if two different dosing strategies for evacetrapib will have essentially the same effect on the body. The study will also explore the effect of a low fat meal on how the body absorbs evacetrapib. This study will last at least 15 weeks, not including screening. Screening is required within 28 days prior to the date of first dosing.

Timeline

Start
2014-09
Primary completion
2015-04
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Evacetrapib Small molecule Oral

Indications

No indication recorded.